【摘要】 目的 探究奥希替尼联合贝伐珠单抗治疗EGFRT 790M突变晚期非小细胞型肺癌(NSCLC)患者的有效性和安全性。方法 选取82例EGFR T790M突变晚期NSCLC患者，按单双号分2组。对照组41例采用奥希替尼治疗，研究组41例采用奥希替尼联合贝伐珠单抗治疗。经过4个周期的治疗，对2组治疗的有效性和安全性进行评估。结果治疗后研究组客观缓解率(ORR)、疾病控制率(DCR)和T淋巴细胞亚群(CD3~+、CD4~+、CD4~+/CD8~+)水平均高于对照组(P<0.05),研究组癌胚抗原(CEA)、人细胞角蛋白21-1(cyfra21-1)、糖类抗原CA125(CA125)水平低于对照组(P<0.05)。2组贫血、皮疹、肝功能损伤、胃肠道反应、蛋白尿和高血压等不良反应分级为1～2级，差异不显著(P>0.05)。结论 奥希替尼联合贝伐珠单抗一线治疗EGFR T790M突变晚期NSCLC,可改善患者免疫功能，降低肿瘤标志物水平，临床疗效高，安全性佳。更多还原

【Abstract】 Objective To investigate the efficacy and safety of osimertinib combined with bevacizumab in patients with EGFRT 790M mutated advanced non-small cell lung cancer(NSCLC).Methods A total of 82 patients with EGFR T790M mutation advanced NSCLC were selected and divided into 2 groups according to odd and even number.41 patients in the control group were treated with osimertinib and 41 patients in the study group were treated with osimertinib combined with bevacizumab.After 4 cycles of treatment, the efficacy and safety of the 2 groups were evaluated.Results After treatment, the objective remission rate(ORR),disease control rate(DCR) and T lymphocyte subsets(CD3~+,CD4~+,CD4~+/CD8~+) levels in the study group were higher than those in the control group(P<0.05).The levels of carcinoembryonic antigen(CEA),human cytokeratin 21-1(cyfra21-1) and carbohydrate antigen CA125(CA125) in the study group were lower than those in the control group(P<0.05).The adverse reactions such as anemia, rash, liver function damage, gastrointestinal reactions, proteinuria and hypertension in the 2 groups were graded as 1-2,and the difference was not statistically significant(P>0.05).Conclusion Osimertinib combined with bevacizumab as first-line treatment for advanced NSCLC with EGFR T790M mutation can improve the immune function of patients, reduce the level of tumor markers, with high clinical efficacy and good safety.更多还原